Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the announcement of encouraging trial results. With the stock currently trading at $0.

With GLP-1-related drugs having won the race to weight loss approval, attention at many obesity-focused biopharmas has turned ...

Oppenheimer reiterated an Outperform rating on Veru Inc. (NASDAQ:VERU), which has seen remarkable momentum with a 200% return over the past year and a 96% gain year-to-date. Anticipation is building ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Veru Inc. Currently has a Zacks ...

Barclays PLC lifted its position in shares of Veru Inc. (NASDAQ:VERU – Free Report) by 309.2% during the 3rd quarter, ...